AM-Pharma
Focus: AM-Pharma is a mid-sized European biotech company founded in 2002, headquartered in Utrecht, Netherlands, focused on alkaline phosphatase and related enzyme therapies across oncology, neurology, and infectious diseases. With 51-200 employees and public status, it operates as a specialized therapeutic developer rather than a broad-spectrum player.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
51-200
Open Jobs
0
About AM-Pharma
AI assessmentNot HiringNo open roles listed right now. Follow AM-Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Pre-Launch
Topical corticosteroid foam addressing inflammatory bowel disease—ANDA pathway suggests generic-competitive positioning rather than branded premium.
Help build intelligence for AM-Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.